Continuous intratympanic infusion of gentamicin via a microcatheter in Menière's disease

J Schoendorf1, P Neugebauer, O Michel

  • 1Department of Otorhinolaryngology, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany. jakob.schoendorf@uni-koeln.de

Insights

Continuous gentamicin infusion for Meniere's disease provided good vertigo control in 8 patients. However, this method resulted in significant hearing loss and was found to be inferior to other treatments.

Area of Science:

  • Otolaryngology
  • Neurosurgery
  • Pharmacology

Background:

  • Meniere's disease causes disabling vertigo and vomiting.
  • Patients often have significant hearing loss on the affected side.
  • Previous treatments for Meniere's disease have varying efficacy and side effect profiles.

Purpose of the Study:

  • To evaluate the efficacy and safety of continuous gentamicin infusion for disabling Meniere's disease.
  • To assess the impact of this treatment on vertigo control and hearing function.
  • To compare continuous gentamicin infusion with other treatment modalities.

Main Methods:

  • 11 patients with disabling Meniere's disease received continuous gentamicin infusion via microcatheter.
  • Gentamicin was delivered at 40 mg/day directly in front of the round window using an insulin pump.
  • Treatment was discontinued upon signs of vestibular dysfunction.

Main Results:

  • 8 out of 11 patients achieved good control of vertiginous spells.
  • 8 patients experienced complete hearing loss in the affected ear; 1 had slight worsening, and 1 had no change.
  • No correlation was found between cumulative gentamicin dosage and hearing loss.

Conclusions:

  • Continuous gentamicin infusion can effectively control vertigo in Meniere's disease.
  • This method is associated with a high incidence of hearing loss.
  • Continuous infusion appears inferior to other gentamicin application methods regarding hearing preservation and hospitalization duration.